Drug Store News - Wyeth launches generic version of Protonix
Wyeth last month announced the U.S. launch of its own generic version of Protonix (pantoprazole) in response to generic launches by Teva Pharmaceuticals, Sun Pharmaceutical and Caraco Pharmaceutical. The patent on Protonix is not set to expire until July 2010. Wyeth and Altana Pharma AG–recently acquired by Wyeth’s business partner Nycomed–sued Teva and Sun Pharmaceuticals for patent infringement based on Teva’s and Sun’s filing of applications seeking Food and Drug Administration approval to market generic versions of Protonix.
Related Results
AHP Posts Flat Earnings But Gears Up for Growth.
Court Takes Matter of Wyeth’s Motion for Preliminary Injunction Under Advisem…
West Nile Virus infection in a renal transplant recipient
Prevacid held slight lead in proton pump inhibitor sales to retailers for 200…
Colorado Medicaid instituted a limit of eight prescriptions per patient at an…
The court did not rule on the validity of the patent, but rather concluded that, based on the limited record before it, Wyeth and Nycomed were not entitled to a preliminary injunction.
COPYRIGHT 2008 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2008 Gale, Cengage Learning
